Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA margin is N/A as of Tuesday, October 6, 2026.
EBITDA MARGIN
N/A
Market Cap
$1.40M
EBITDA Margin
-22.87%
TTM Avg
-29.13%
3Y Avg
-70.31%
5Y Avg
-127.65%
Market Cap
$1.45M
EBITDA Margin
-75.46%
TTM Avg
-92.89%
3Y Avg
-421.55%
5Y Avg
-389.33%
Market Cap
$1.47M
EBITDA Margin
-1231.39%
TTM Avg
-651.84%
3Y Avg
-512.06%
5Y Avg
-24032.93%
Market Cap
$1.48M
EBITDA Margin
-346.64%
TTM Avg
-376.56%
3Y Avg
-438.06%
5Y Avg
-395.70%
Market Cap
$1.50M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.12M
EBITDA Margin
-40873.19%
TTM Avg
-40873.19%
3Y Avg
-21172.28%
5Y Avg
-10780.34%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| NewcelX Ltd. (NCEL) | $1.39M | N/A | N/A | N/A | N/A |
| Artelo Biosciences, Inc. (ARTL)vs › | $1.40M | N/A | N/A | N/A | N/A |
| NEXGEL, Inc. (NXGL)vs › | $1.40M | -22.87% | -29.13% | -70.31% | -127.65% |
| Genprex, Inc. (GNPX)vs › | $1.37M | N/A | N/A | N/A | N/A |
| INVO Fertility, Inc. (IVF)vs › | $1.45M | -75.46% | -92.89% | -421.55% | -389.33% |
| PMGC Holdings Inc. (ELAB)vs › | $1.47M | -1231.39% | -651.84% | -512.06% | -24032.93% |
| Curis, Inc. (CRIS)vs › | $1.48M | -346.64% | -376.56% | -438.06% | -395.70% |
| Lakewood-Amedex Biotherapeutics, Inc. (LABT)vs › | $1.50M | N/A | N/A | N/A | N/A |
| Jupiter Neurosciences, Inc. (JUNS)vs › | $1.12M | -40873.19% | -40873.19% | -21172.28% | -10780.34% |
| Propanc Biopharma, Inc. (PPCB)vs › | $1.16M | N/A | N/A | N/A | N/A |
Gross Margin
0.0%
EBITDA Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
